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I read with interest the article titled ‘‘Effect of main-
tenance hemodialysis on diastolic left ventricular function in
end-stage renal disease’’ by Duran et al.1 in the October 2010
issue of this Journal and would like to present some
comments on this article. The authors conducted an
intriguing study to determine whether a change in cardiac
function occurs after commencing hemodialysis with
arteriovenous fistula. To better address this issue, I believe
that several points need to be explored: the duration of the
follow-up period, the method used to detect change in the
primary endpoint and other factors that might have
influenced the primary endpoint.
First, the length of the follow-up period may have played
an important role in the neutral result of the study. Left
ventricular (LV) diastolic dysfunction, which includes
abnormal diastolic distensibility, delayed relaxation and
impaired filling, may result from pathologic ventricular
hypertrophy (which interferes with myofilament cross-
bridge detachment), regional asynchrony from myocardial
ischemia or heightened cardiac afterload.2 LV stiffness also
contributes to diastolic dysfunction and presents as an
increasing LV operating mass.3 Considering the chronolo-
gical course of LV hypertrophy (LVH), which includes an
increasing LV mass over time that leads to LV diastolic
dysfunction, the period of follow-up is important. In a
seminal article, Lo et al. searched for predictive factors
associated with LVH in non-diabetic hemodialysis patients
and prospectively identified several biochemical and phy-
sical parameters in a single cohort over a two-year period.
They found that systolic blood pressure, atrial natriuretic
peptide, albumin levels and hemoglobin levels can each be
used as predictors of LV mass index following the initiation
of hemodialysis.4 Bajraktari et al. utilized tissue Doppler to
assess LV filling pressure and identified reduced systolic
myocardial velocity and advanced age as factors associated
with increasing LV filling pressure over a median time span
of 4.4 years.5 Losi et al. performed a cross-sectional study in
a group of maintenance hemodialysis patients (typical
duration 6–24 months) to investigate the relationship
between LV diastolic dysfunction and echocardiographic
backscatter from the myocardium; they observed that
approximately 40% of the patients presented evidence of
diastolic dysfunction.6 In the above studies, the average
length of the follow-up period ranged from just over half a
year to 4 years. The results of these studies support the
importance of the duration of the follow-up period when
identifying myocardial remodeling in end stage renal
disease patients undergoing hemodialysis. As the median
duration of the follow-up period in Duran’s study was
approximately 2 months,1 the myocardial change is expect-
edly small, notwithstanding the possibility of a more subtle
change in diastolic dysfunction even without an increasing
LV mass.2
Second, the method used to detect LV diastolic dysfunc-
tion may have been inferior to other options.
Echocardiography is inherently deficient in determining
the echo window and spatial resolution, and it suffers from
an operator-dependent nature.7 The volume-dependent
effect also attenuates its diagnostic accuracy. Cardiac
magnetic resonance imaging (MRI) is a new volume-
independent modality that provides a detailed depiction
of LV geometry and structural variation. Cardiac MRI has
been validated in end-stage renal disease patients for both
the detection of LVH and LV mass quantification, and this
method of quantification correlates fairly well with cardio-
vascular outcome.8,9 Moreover, cardiac MRI can detect
smaller changes in the myocardium. Myerson et al.
examined a selected group of LVH patients and found that
cardiac MRI was able to accurately determine a statistically
significant LV mass change (10 g) in approximately 80% of
the patients for whom a corresponding change could be
detected using 2-D echocardiography.9 In the field of
diastolic dysfunction, there is a surging interest in using
newer techniques, such as left atrium circulation transit time
(LATT) and late gadolinium enhancement (LGE) sequence,
to determine myocardial fibrosis;7 good correlations with
echocardiographic findings have been demonstrated. This
imaging modality offers a promising method for earlier
detection of diastolic dysfunction, especially for the small
number of patients who exhibit different degrees of LV
pathology.
The inability to detect LV and even right ventricular
function change in the study by Duran et al.1 may have also
been the result (to a lesser degree) of a decreased severity of
the LVH in their patient population, which may reflect the
lower frequency of angiotensin-converting enzyme inhibi-
tor/angiotensin receptor blocker use. The pre-dialysis blood
pressure of their patients was also better controlled (average
systolic/diastolic 135/83 mmHg), possibly attenuating an
otherwise detectable LV change. In summary, the length of
the follow-up period played an important role in the neutral
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result of Duran’s study, and a more accurate method for the
detection of LV diastolic dysfunction might have identified
a significant difference even in the short term. As time
passes, newer technologies emerge that will allow for earlier
detection of even trivial abnormalities.
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